ICCC vs NBIX · rev $26.5M vs P/E 45, rev $2.36B
ImmuCell Corporation (ICCC) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
ImmuCell Corporation (ICCC) is a biotechnology company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ICCC revenue for 2024-12-31 was $26.5M. Net income was -$2.2M. Revenue was up 51.6% from 2023-12-31 to 2024-12-31. ICCC currently screens at market cap $58.9M.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
ICCC currently screens at market cap $58.9M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the ICCC and NBIX stock pages for the full models.
Not investment advice.